Get in touch

*5555

mymail@mailservice.com

Drug Discovery

Drug discovery is the major focus of our laboratory, (curcumin), antiaging agents (resveratrol), mitochondria-targeted molecules, DDQ, MitoQ, SS31, and mitochondria division inhibitor 1 (Mdivi-1) against mutant proteins Abeta, phosphorylated Tau and mutant huntingtin. DDQ molecules are designed, synthesized, and tested in our laboratory and extensively published in cell and mouse models of aging, Amyloid beta, phosphorylated tau, and Investigational Drug (IND).

Studies at Reddy lab explored the protective effects of DDQ, a novel molecule developed in our lab, against AD pathology using various models, including humanized Abeta knockin mice, APP transgenic mice, tau transgenic mice, and HT22 hippocampal neuronal cells. DDQ treatment significantly improved cognitive performance and neurodegenerative markers, restoring mitochondrial function and dynamics, reducing amyloid-beta toxicity, and enhancing synaptic plasticity. In tau transgenic mice, DDQ alleviated tau-induced toxicity and neuroinflammation, upregulated mitophagy markers, and improved mitochondrial homeostasis, as supported by electron microscopy. In HT22 cells, DDQ reduced mitochondrial fragmentation and promoted the expression of anti-aging and synaptic proteins, enhancing cellular resilience. Overall, DDQ improved mitochondrial function, synaptic health, and cognitive abilities, highlighting its potential as a therapeutic candidate for AD by targeting mitochondrial dysfunction and modulating neurodegeneration pathways, with ongoing studies to investigate its long-term effects and mechanisms.